| Literature DB >> 28114824 |
Alessia Bino1, Anna Baldisserotto1, Emanuela Scalambra1, Valeria Dissette1, Daniela Ester Vedaldi2, Alessia Salvador2, Elisa Durini1, Stefano Manfredini1, Silvia Vertuani1.
Abstract
An ever-increasing incidence of skin neoplastic diseases is registered. Therefore, it is important to protect the skin from the UV radiation that reaches the epidermis and dermis but also to block ROS generated by them. Our attention was attracted in developing new compounds provided with both UV filtering and antioxidant capacities. To this end, 2-phenyl-1H-benzimidazole-5-sulfonic acid (PBSA), a known UV filter, was selected as lead compound for its lack of antioxidant activity, high water solubility and good safety profile. PBSA was sequentially modified introducing hydroxyls on the phenyl ring and also substituting the functional group in position 5 of the benzimidazole ring. At the end of the synthetic study, a new, very potent class of antioxidants has been obtained. Surprisingly some of the developed molecules, while devoid of significant UV-filtering activity was endowed with potent UV-filtering booster capability if associated with known commercial UVB and UVA filters.Entities:
Keywords: Benzimidazole; UV booster; antioxidant; reactive oxygen species; sunscreens
Mesh:
Substances:
Year: 2017 PMID: 28114824 PMCID: PMC6010047 DOI: 10.1080/14756366.2016.1265523
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051
Scheme 1.Synthesis of compounds 2–15.
Results of antioxidant assays. Each value was obtained from three experiments (Mean ± SE).
| Product | DPPH (μmolTrolox/mmol)( | FRAP (μmolTrolox/mmol)( | PCL (μmolTrolox/mmol)( |
|---|---|---|---|
| PBSA | < LOQa | 0.79 ± 0.06 | < LOQa |
| 2.04 ± 0.15 | 12.23 ± 0.25 | 11.36 ± 0.08 | |
| 2145.31 ± 45.8 | 2707.29 ± 29.52 | 22,838 ± 836,26 | |
| 2.03 ± 0.09 | 16.22 ± 0.89 | 2.06 ± 0.05 | |
| 21.41 ± 043 | 19.87 ± 0.22 | 159.1 ± 4.3 | |
| 1362.12 ± 133.96 | 2713.3 ± 45.17 | 1924.35 ± 101.82 | |
| 1.67 ± 0.08 | 21.94 ± 0.12 | 9.66 ± 0,04 | |
| 1974.58 ± 16.89 | 2663.21 ± 32.53 | 19190.6 ± 443.18 | |
| 16.47 ± 0.54 | 37.3 ± 0.35 | 198.53 ± 2.65 | |
| 0.87 ± 0.05 | 23.04 ± 0.09 | 10.93 ± 0.05 | |
| 1811.02 ± 61.7 | 2723.19 ± 35.74 | 1614.675 ± 19.95 | |
| 1771.82 ± 84.75 | 2433.28 ± 21.74 | 13174.31 ± 240.68 | |
| 32.48 ± 2.38 | 31.63 ± 1.96 | 160.26 ± 4.09 | |
| 1.185 ± 0.02 | 2.62 ± 0.06 | 6.98 ± 0.27 | |
| 1241.03 ± 9.43 | 2355.15 ± 52.55 | 1515.65 ± 75.56 |
LOQa limit of quantification.
Values of λ max and ɛ.
| λ max (nm) | ɛ | |
|---|---|---|
| 302 | 25 000 | |
| 308 | 25 000 | |
| 313 | 23 000 | |
| 315 | 21 000 | |
| 318 | 23 000 | |
| 328 | 22 200 | |
| 306 | 24 000 | |
| 311 | 16 000 | |
| 315 | 14 000 | |
| 315 | 17 000 | |
| 325 | 12 000 | |
| 317 | 21 000 | |
| 321 | 20 000 | |
| 312 | 24 000 | |
| 332 | 17 000 |
Antioxidant activity of finished formulations.
| Formulation | PCL μmol Trolox/g formulation( |
|---|---|
| <LOQ | |
| 0.33 ± 0.03 | |
| 2212.09 ± 68.35 | |
| 0.06 ± 0.02 | |
| 0.95 ± 0.02 | |
| 101.98 ± 1.08 | |
| 2972.107 ± 145.63 | |
| 8.66 ± 0.04 | |
| 0.5 ± 0.02 | |
| 153.35 ± 8.14 | |
| 1373.39 ± 19.43 | |
| 4.97 ± 0.17 | |
| 0.16 ± 0.02 | |
| 86.99 ± 6.95 |
Values are the mean of three independent determinations.
Limit of quantification.
. Protecting efficacy.
| Formulatedcompounds | SPF ( | UVA/UVB ( | UVAPF ( | λc |
|---|---|---|---|---|
| 4.56 ± 1.09 | 0.26 ± 0.05 | 1.04 ± 0.06 | 333 | |
| 4.74 ± 0.15 | 0.51 ± 0.01 | 1.36 ± 0.07 | 346 | |
| 9.83 ± 0.64 | 0.74 ± 0.04 | 3.63 ± 0.23 | 358 | |
| 2.22 ± 0.13 | 0.96 ± 0.01 | 1.06 ± 0.07 | 355 | |
| 2.18 ± 0.14 | 1.13 ± 0.01 | 1.21 ± 0.04 | 370 | |
| 5.99 ± 0.12 | 0.89 ± 0.03 | 2.72 ± 0.08 | 383 | |
| 5.20 ± 0.20 | 0.78 ± 0.02 | 1.90 ± 0.09 | 368 | |
| 3.57 ± 0.23 | 1.10 ± 0.05 | 1.89 ± 0.05 | 380 | |
| 1.96 ± 0.14 | 1.01 ± 0.02 | 1.06 ± 0.08 | 378 | |
| 2.85 ± 0.22 | 0.90 ± 0.01 | 1.35 ± 0.1 | 381 | |
| 2.21 ± 0.17 | 1.00 ± 0.04 | 1.88 ± 0.12 | 370 | |
| 2.85 ± 0.17 | 1.27 ± 0.02 | 1.58 ± 0.10 | 368 | |
| 6.01 ± 0.31 | 0.70 ± 0.05 | 2.04 ± 0.11 | 350 | |
| 3.69 ± 0.24 | 0.96 ± 0.08 | 1.87 ± 0.08 | 382 |
Values are the mean of three independent determinations, each of which at least five readings.
Wavelength at which the integral of the spectral absorbance curve reaches 90% of the area under the curve from 290 to 400 nm.
Cytotoxicity results expressed as IC50 values on NCTC-2544 cells.
| Compounds | IC50 (μM) |
|---|---|
| >50 | |
| 26.4 ± 2.7 | |
| >50 | |
| >50 | |
| >50 | |
| 23.1 ± 2.9 | |
| 26.1 ± 2.4 | |
| >50 | |
| >50 | |
| >50 | |
| >50 | |
| >50 | |
| >50 | |
| >50 | |
| >50 |
Phototoxicity test data.
| Compound | Concentration (μM) | % Cell survival | ||
|---|---|---|---|---|
| UVA 20 J/cm2 | UVB 0.5 J/cm2 | UVB 1 J/cm2 | ||
| 69.1 ± 3.2% | 63.1 ± 3.2% | 33.8 ± 3.1% | ||
| 50 | 74.5 ± 1.4% | 75.2 ± 4.5% | 64.2 ± 3.1% | |
| 20 | 77.3 ± 2.8% | 78.0 ± 3.5% | 46.7 ± 3.4% | |
| 50 | 77.4 ± 4.0% | 71.5 ± 2.5% | 58.1 ± 2.6% | |
| 50 | 76.9 ± 2.0% | 74.3 ± 3.2% | 37.7 ± 1.7% | |
| 50 | 79.0 ± 6.0% | 70.8 ± 3.9% | 38.6 ± 3.7% | |
| 20 | 18.4 ± 2.3% | 59.3 ± 3.4% | 29.7 ± 2.1% | |
| 20 | 72.8 ± 2.9% | 74.2 ± 1.3% | 44.0 ± 4.1% | |
| 50 | 62.9 ± 4.3% | 72.8 ± 1.0% | 43.9 ± 3.4% | |
| 50 | 3.7 ± 0.5% | 1.1 ± 0.3% | 0.5 ± 0.1% | |
| 50 | 4.8 ± 0.6% | 19.8 ± 2.4% | 3.5 ± 0.3% | |
| 50 | 1.2 ± 0.2% | 45.6 ± 2.6% | 27.0 ± 2.4% | |
| 50 | 74.3 ± 2.0% | 76.3 ± 3.6% | 64.5 ± 3.5% | |
| 50 | 80.7 ± 1.3% | 69.0 ± 0.2% | 57.5 ± 2.4% | |
| 50 | 76.7 ± 3.4% | 74.2 ± 3.4% | 58.4 ± 2.5% | |
| 50 | 12.2 ± 1.3% | 60.1 ± 2.3% | 25.6 ± 2.7% | |
Evaluation of photostability.
| Product | Residual product ( |
|---|---|
| PBSA | 96.7% ± 1.8% |
| 94.9% ± 0.8% | |
| 98.4% ± 0.9% |
Values are the mean of four independent experiments.
Figure 4.Stability studies in formulation (formulations were submitted to accelerated aging at 40 °C for 63 days).
Figure 5.SPF values (reported in dark grey) and UVA-PF values (reported in light grey) of the tested formulations.
Mixed commercial filters used in the formulations.
| UV filter composition | SPF 15 | SPF 30 |
|---|---|---|
| INCI name | Amount | Amount |
| Butyl methoxydibenzoylmethane | 2.3% | 4.7% |
| Ethylhexyl methoxycinnamate | 4.0% | 8.0% |
| Octocrylene | 4.0% | 8.0% |
In vivo evaluation of selected formulations.
| Emulsion | |
|---|---|
| Oxisol (12) 3% | 2.68 |
| Mixed filters SPF 15 | 15.78 |
| Oxisol (12) 3%+Mixed Filters SPF15 | 21.74 |